Page last updated: 2024-10-29

avapro and Pulmonary Fibrosis

avapro has been researched along with Pulmonary Fibrosis in 2 studies

Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.

Pulmonary Fibrosis: A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Alsayed, HA1
Mohammad, HMF1
Khalil, CM1
El-Kherbetawy, MK1
Elaidy, SM1
Marut, W1
Kavian, N1
Servettaz, A1
Hua-Huy, T1
Nicco, C1
Chéreau, C1
Weill, B1
Dinh-Xuan, AT1
Batteux, F1

Other Studies

2 other studies available for avapro and Pulmonary Fibrosis

ArticleYear
Autophagy modulation by irbesartan mitigates the pulmonary fibrotic alterations in bleomycin challenged rats: Comparative study with rapamycin.
    Life sciences, 2022, Aug-15, Volume: 303

    Topics: Animals; Autophagy; Bleomycin; Epithelial-Mesenchymal Transition; Irbesartan; Mammals; Pulmonary Fib

2022
Amelioration of systemic fibrosis in mice by angiotensin II receptor blockade.
    Arthritis and rheumatism, 2013, Volume: 65, Issue:5

    Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Biphenyl Compoun

2013